CClinicalTrials.gg
WithdrawnNCT01736501BabySeqUpdated Nov 12, 2025

Surveying Parents About Genome Screening of Newborns

An interventional study of Genetics education at baseline and Hypothetical genomic scenarios at follow-up in Parents of Healthy Newborns, sponsored by Brigham and Women's Hospital. Withdrawn at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by Brigham and Women's Hospital · Not applicable and Interventional

Why this study was withdrawn
This was not a clinical trial.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Sex
All
01

Study summary

A 10 minute baseline survey will be administered to parents of healthy newborn infants while in the hospital after delivery at Brigham and Women's Hospital, to be followed by a 25 minute survey 3-24 months later. We will measure parents' attitudes and preferences related to genome screening of newborns. The specific aims of this study are:

  1. To investigate whether parents' opinions regarding genome screening of newborns change between the first 48 hours post-partum and 3-24 months post-partum.

    a. We hypothesize that there will not be significant differences between interest in genome screening results in the 48 hours post-partum compared to 3-24 months post-partum.

  2. To determine whether seeing hypothetical genome screening results affects parents' decisions regarding whether they would want genome screening for their newborn.

    1. We expect many parents to state initially (in the 48 hours post-partum) that they would elect to have genome screening for their newborn if it were available. In the follow-up survey, half of study participants will receive hypothetical scenarios in which they will need to struggle with the probabilistic and ambiguous nature of the information that could be derived from genome sequencing. We will examine whether this alters their preferences. We will also explore whether parents who receive hypothetical genome screening results scenarios are more likely to alter their preferences than parents who do not receive hypothetical scenarios.
02

Conditions studied

  • Parents of Healthy Newborns
03

In context

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,236 studies on the registry; 224 are open to participants now.

Of its 116 completed or terminated interventional studies of FDA-regulated products, 64 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Parent of a healthy newborn in the BWH Department of Obstetrics
  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • Impaired decision-making capacity
  • Newborn with life-threatening health concerns in the 48 hours post-partum
05

Study design

Phase
Not applicable
Allocation
Randomized
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • No intervention
    Baseline1-demographics

    Baseline survey- demographics only

  • Other
    Baseline1 w/genetics

    Genetics education, baseline interest in genome screening - 1

    Other: Genetics education at baseline

  • Other
    Baseline2-demographics

    Baseline survey- demographics only

    Other: Hypothetical genomic scenarios at follow-up

  • Other
    Baseline2 w/genetics

    Genetics education, baseline interest in genome screening - 2

    Other: Genetics education at baseline · Other: Hypothetical genomic scenarios at follow-up

Interventions

  • OtherGenetics education at baseline
  • OtherHypothetical genomic scenarios at follow-up
06

What researchers measure

Primary outcomes

  1. Interest in genome screening for newborn if this service were available through a research study

    This is a question created by the investigators. It uses a 5-point Likert scale to measure parents' self-reported interest in genome screening for their newborn.

    Time frame: Change between baseline and 3-24 month follow-up

Secondary outcomes

  1. Rate of refusal of newborn screening

    Newborn screening refusals are very rare. When they occur, they are tracked by nurses on the postpartum inpatient unit. At the start of all shifts for study recruitment, the research assistant will ask the nurse-in-charge if any patients refused newborn screening since the previous study recruitment shift.

    Time frame: baseline

Other outcomes

  1. Parental Stress

    Parenting Stress Index- short form

    Time frame: 3-28 month follow-up

  2. Postpartum bonding

    Postpartum Bonding Questionnaire

    Time frame: 3-28 month follow-up

07

Study locations

1 site
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
08

References and documents

Publications

  • Waisbren SE, Back DK, Liu C, Kalia SS, Ringer SA, Holm IA, Green RC. Parents are interested in newborn genomic testing during the early postpartum period. Genet Med. 2015 Jun;17(6):501-4. doi: 10.1038/gim.2014.139. Epub 2014 Dec 4. PubMed 25474344 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01736501
Lead sponsor
Brigham and Women's Hospital
Responsible party
Robert C. Green, MD, MPH (Lecturer on Medicine & Associate Director for Research, Partners Center for Personalized Genetic Medicine, Brigham and Women's Hospital) — Principal investigator
First posted
Nov 29, 2012
Last update
Nov 12, 2025

Study contacts

Robert C. Green, MD, MPH
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion